LEADER 03849nam 2200625 a 450 001 9910970659603321 005 20251116141110.0 010 $a9780309183888 010 $a030918388X 010 $a9780309558143 010 $a030955814X 010 $a9780309528542 010 $a0309528542 035 $a(CKB)110986584752960 035 $a(EBL)3375292 035 $a(Au-PeEL)EBL3375292 035 $a(CaPaEBR)ebr10038562 035 $a(OCoLC)923254924 035 $a(MiAaPQ)EBC3375292 035 $a(Perlego)4737909 035 $a(BIP)53856187 035 $a(BIP)6397731 035 $a(EXLCZ)99110986584752960 100 $a20000708d2000 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aExtending medicare reimbursement in clinical trials /$fCommittee on Routine Patient Care Costs in Clinical Trials for Medicare Beneficiaries ; Henry J. Aaron and Hellen Gelband, editors 205 $a1st ed. 210 $aWashington, D.C. $cNational Academy Press$dc2000 215 $a1 online resource (86 p.) 300 $aDescription based upon print version of record. 311 08$a9780309068888 311 08$a0309068886 320 $aIncludes bibliographical references (p. 65-66). 327 $a""Front Matter""; ""Acknowledgments""; ""Contents""; ""Executive Summary""; ""1 Clinical Trials in the United States""; ""2 Paying for Patient Care in Clinical Trials""; ""3 Recommendations for Medicare Clinical Trial Reimbursement""; ""References""; ""APPENDIX A Glossary, Acronyms, and Abbreviations""; ""APPENDIX B Committee Biographies"" 330 $aIncreasingly over the past five years, uncertainty about reimbursement for routine patient care has been suspected as contributing to problems enrolling people in clinical trials. Clinical trial investigators cannot guarantee that Medicare will pay for the care required, and they must disclose this uncertainty to potential participants during the informed consent process. Since Medicare does not routinely "preauthorize" care (as do many commercial insurers) the uncertainty cannot be dispelled in advance. Thus, patients considering whether to enter trials must assume that they may have to pay bills that Medicare rejects simply because they have enrolled in the trial. This report recommends an explicit policy for reimbursement of routine patient care costs in clinical trials. It further recommends that HCFA provide additional support for selected clinical trials, and that the government support the establishment of a national clinical trials registry. These policies (1) should assure that beneficiaries would not be denied coverage merely because they have volunteered to participate in a clinical trial; and (2) would not impose excessive administrative burdens on HCFA, its fiscal intermediaries and carriers, or investigators, providers, or participants in clinical trials. Explicit rules would have the added benefit of increasing the uniformity of reimbursement decisions made by Medicare fiscal intermediaries and carriers in different parts of the country. Greater uniformity would, in turn, decrease the uncertainty about reimbursement when providers and patients embark on a clinical trial. 606 $aMedicare 606 $aClinical trials$zUnited States 606 $aMedical care, Cost of$zUnited States 615 0$aMedicare. 615 0$aClinical trials 615 0$aMedical care, Cost of 676 $a338.4/33621/0973 701 $aAaron$b Henry J$0113318 701 $aGelband$b Hellen$01808924 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910970659603321 996 $aExtending medicare reimbursement in clinical trials$94359432 997 $aUNINA